Fibrolamellar hepatocellular carcinoma

Last updated
Fibrolamellar hepatocellular carcinoma
Other namesFHCC
Fibrolamellar hepatocellular carcinoma -2- very high mag.jpg
Micrograph of fibrolamellar hepatocarcinoma showing the characteristic laminated fibrosis between the tumor cells with a low NC ratio. H&E stain.
Specialty Oncology   OOjs UI icon edit-ltr-progressive.svg

Fibrolamellar carcinoma (FLC) is a rare form of carcinoma that typically affects young adults and is characterized, under the microscope, by laminated fibrous layers interspersed between the tumor cells. [1] It has been estimated that 200 new cases are diagnosed worldwide each year. [2] However, in light of recent advances in our molecular understanding, this has recently been revised to suggest it may be at least ten times more common. [3] FLC, also known as fibrolamellar hepatocellular carcinoma, is different from the more common hepatocellular carcinoma (HCC) in that it afflicts young people with normal liver function and no known risk factors. [1] [2] [4] [5]

Contents

Cause

A 2014 study showed the presence of the DNAJB1-PRKACA chimeric transcript (resulting from a 400kb somatic deletion on chromosome 19) in 100% of the FLCs examined (15/15). [6] [7] This gene fusion has been confirmed in many other studies. [8] [9] [10] That this genomic deletion is sufficient to produce FLC was shown by creating this deletion, and formation of the DNAJB1::PRKACA chimeric gene, using CRISPR/Cas9 in the livers of mice. [11] [12] That the actual formation of the DNAJB1::PRKACA was responsible, and not the deletion, was shown by expression of the DNAJB1::PRKACA from a transposon. [11] To determine if the DNAJB1::PRKACA was only involved in triggering the tumor, or if it continued to drive the tumor, a small hairpin RNA was used to eliminate the DNAJB1::PRKACA. The tumors died, which demonstrated not only that DNAJB1::PRKACA is continuing to drive FLC, but that the tumor has become oncogenically addicted. [13]

Pathology

The histopathology of FLC is characterized by laminated fibrous layers, interspersed between the tumor cells. Cytologically, the tumor cells have a low nuclear to cytoplasmic ratio with abundant eosinophilic cytoplasm. [1] Tumors are non-encapsulated, but well circumscribed, when compared to conventional HCC (which typically has an invasive border).[ citation needed ]

Diagnosis

Due to lack of symptoms, until the tumor is sizable, this form of cancer is often advanced when diagnosed. Symptoms include vague abdominal pain, nausea, abdominal fullness, malaise and weight loss. They may also include a palpable liver mass. [14] Other presentations include jaundice, ascites, fulminant liver failure, encephalopathy, gynecomastia (males only), thrombophlebitis of the lower limbs, recurrent deep vein thrombosis, anemia and hypoglycemia.[ citation needed ]

The usual markers for liver disease – aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase – are often normal or only slightly elevated. FLC often does not produce alpha fetoprotein (AFP), a widely used marker for conventional hepatocellular carcinoma. In a subset of FLC patients elevated plasma neurotensin levels may be present. [15] Likewise, in a subset of FLC patients, elevated serum vitamin B12 binding globulin levels may be present. [16]

Diagnosis is normally made by imaging (ultrasound, CT or MRI) and biopsy. [17] However, even with a biopsy, there is often disagreement over the diagnosis. [17] Since the characterization of the DNAJB1::PRKACA fusion, the most reliable diagnosis is through molecular characterization such as PCR to detect the fusion, [7] [18] or genomic sequencing, or using a fluorescent in-situ hybridization. [8]

Treatment

FLC can often be surgically removed. Liver resection is the optimal treatment and may need to be performed more than once, since this disease has a very high recurrence rate. [19] Due to such recurrence, periodic follow-up medical imaging (CT or MRI) is necessary. [19]

When the tumor cannot be removed surgically or when there is distant spread, many different systemic therapies are currently being used to treat the disease. However, no standard of care currently exists for FLC. Consequently, there remains a pressing need to identify proven, effective systemic therapies for the cancer. [2] [20] [5] Radiotherapy has been used but data is limited concerning its use.

The Fibrolamellar Registry, (http://fibroregistry.org) [21] a patient and family run medical registry has collected data from over 250 patients. This work has been used in multiple publications which include extended information on patient outcomes, efficacy of immune checkpoint inhibitors, efficacy of specific drugs and understanding the basis of high ammonia in FLC. [19] [22] [23] [18]

The Fibroregistry [21] has answers to frequently asked questions (https://fibroregistry.org/faq-fibrolamellar/ ) as well as plain-language summaries of the science literature for understanding the success rate of some treatment approaches (https://fibroregistry.org/published-papers/ ). The FibroFoundation has resources available on different FLC treatment options. [24]

The survival rate for FLC largely depends on whether (and to what degree) the cancer has metastasized, i.e. spread to the lymph nodes or other organs. Distant spread (metastases), significantly reduces the median survival rate. [19] Five-year survival rates vary between 40 and 90%. [19]

Epidemiology

FLC accounts for 1–10% of primary liver cancers. [25] It typically has a young age at presentation when compared to conventional HCC. Previously it was estimated to be 20–40 years, mean ages 27 years, [26] but when analysis is restricted to those patients who are confirmed with a molecular test to have FLC, the age range is 10-40 and mean age of 21 years. [19] Unlike the more common HCC, patients most often do not have coexistent liver disease such as cirrhosis.

History

This disease was first described by Hugh Edmondson in a 14-year-old female with no underlying liver disease. [27] The name fibrolamellar hepatocellular carcinoma was coined by Craig et al. in 1980. [28] It was not recognized as a distinct form of cancer by the WHO until 2010. [29]

Starting in 2010, some patients and their family members started to examine the molecular basis of FLC. [20] They gathered samples through social media, [30] [31] sequenced the genome, and analyzed the immunological response. Since there are few patients at any one institution, they formed their own medical registry, which allowed them to follow patients as they changed institutions (http://fibroregistry.org). [21] This work led to the identification of the chimeric fusion driver and the first characterization of the transcriptome and proteome. The work was heralded by Francis Collins when he presented to the Senate Appropriations committee [32] and was used by President Obama at the launch of The Precision Medicine Initiative at the White House. [33]

Additional images

Related Research Articles

<span class="mw-page-title-main">Hepatocellular carcinoma</span> Medical condition

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and is currently the most common cause of death in people with cirrhosis. HCC is the third leading cause of cancer-related deaths worldwide.

Liver tumors are abnormal growth of liver cells on or in the liver. Several distinct types of tumors can develop in the liver because the liver is made up of various cell types. Liver tumors can be classified as benign (non-cancerous) or malignant (cancerous) growths. They may be discovered on medical imaging, and the diagnosis is often confirmed with liver biopsy. Signs and symptoms of liver masses vary from being asymptomatic to patients presenting with an abdominal mass, hepatomegaly, abdominal pain, jaundice, or some other liver dysfunction. Treatment varies and is highly specific to the type of liver tumor.

<span class="mw-page-title-main">Everolimus</span> Chemical compound

Everolimus, sold under the brand name Afinitor among others, is a medication used as an immunosuppressant to prevent rejection of organ transplants and as a targeted therapy in the treatment of renal cell cancer and other tumours.

<span class="mw-page-title-main">Viral hepatitis</span> Liver inflammation from a viral infection

Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent infection with relatively rapid onset, or in chronic form, typically progressing from a long-lasting asymptomatic condition up to a decompensated hepatic disease and hepatocellular carcinoma (HCC).

<span class="mw-page-title-main">Carcinoembryonic antigen</span> Glycoprotein secreted into the luminal surface of the epithelia in the gastrointestinal tract

Carcinoembryonic antigen (CEA) describes a set of highly-related glycoproteins involved in cell adhesion. CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Consequently, CEA is usually present at very low levels in the blood of healthy adults. However, the serum levels are raised in some types of cancer, which means that it can be used as a tumor marker in clinical tests. Serum levels can also be elevated in heavy smokers.

Transcatheter arterial chemoembolization (TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.

In oncology, AFP-L3 is an isoform of alpha-fetoprotein (AFP), a substance typically used in the triple test during pregnancy and for screening chronic liver disease patients for hepatocellular carcinoma (HCC). AFP can be fractionated by affinity electrophoresis into three glycoforms: L1, L2, and L3 based on the reactivity with the lectin Lens culinaris agglutinin (LCA). AFP-L3 binds strongly to LCA via an additional α 1-6 fucose residue attached at the reducing terminus of N-acetylglucosamine; this is in contrast to the L1 isoform. It is the L1 isoform which is typically associated with non-HCC inflammation of liver disease condition. The L3 isoform is specific to malignant tumors and its detected presence can serve to identify patients whom need increased monitoring for the development of HCC in high risk populations. AFP-L3% is now being considered as a tumor marker for the North American demographic.

<span class="mw-page-title-main">Sorafenib</span> Chemical compound

Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer, advanced primary liver cancer, FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.

Des-gamma carboxyprothrombin (DCP), also known as protein induced by vitamin K absence/antagonist-II (PIVKA-II), is an abnormal form of the coagulation protein, prothrombin. Normally, the prothrombin precursor undergoes post-translational carboxylation by gamma-glutamyl carboxylase in the liver prior to secretion into plasma. DCP/PIVKA-II may be detected in people with deficiency of vitamin K and in those taking warfarin or other medication that inhibits the action of vitamin K.

<span class="mw-page-title-main">Liver cancer</span> Medical condition

Liver cancer is cancer that starts in the liver. Liver cancer can be primary or secondary. Liver metastasis is more common than that which starts in the liver. Liver cancer is increasing globally.

<span class="mw-page-title-main">PRKACA</span> Protein-coding gene in the species Homo sapiens

The catalytic subunit α of protein kinase A is a key regulatory enzyme that in humans is encoded by the PRKACA gene. This enzyme is responsible for phosphorylating other proteins and substrates, changing their activity. Protein kinase A catalytic subunit is a member of the AGC kinase family, and contributes to the control of cellular processes that include glucose metabolism, cell division, and contextual memory. PKA Cα is part of a larger protein complex that is responsible for controlling when and where proteins are phosphorylated. Defective regulation of PKA holoenzyme activity has been linked to the progression of cardiovascular disease, certain endocrine disorders and cancers.

<span class="mw-page-title-main">Glypican 3</span> Protein-coding gene in the species Homo sapiens

Glypican-3 is a protein that, in humans, is encoded by the GPC3 gene. The GPC3 gene is located on human X chromosome (Xq26) where the most common gene encodes a 70-kDa core protein with 580 amino acids. Three variants have been detected that encode alternatively spliced forms termed Isoforms 1 (NP_001158089), Isoform 3 (NP_001158090) and Isoform 4 (NP_001158091).

<span class="mw-page-title-main">DNAJB1</span> Protein-coding gene in the species Homo sapiens

DnaJ homolog subfamily B member 1 is a protein that in humans is encoded by the DNAJB1 gene.

Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

In transplantation medicine, the Milan criteria are set of criteria applied in consideration of patients with cirrhosis and hepatocellular carcinoma (HCC) for liver transplantation with intent to cure their disease. Their significance derives from a landmark 1996 study in 48 patients by Mazzaferro et al which showed that selecting cases for transplantation according to specific strict criteria led to improved overall and disease-free survival at a four-year time point. These same criteria have since been adopted by the Organ Procurement and Transplantation Network (OPTN) in the evaluation of patients for potential transplantation.The threshold Milan criteria are as follows:

<span class="mw-page-title-main">Brivanib alaninate</span> Chemical compound

Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC, the most common type of liver cancer. Brivanib is no longer in active development.

Resminostat is an orally bioavailable inhibitor of histone deacetylases (HDACs), of which inhibitors are antineoplastic agents.

<span class="mw-page-title-main">Scott W. Lowe</span> American geneticist

Scott William Lowe is Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is recognized for his research on the tumor suppressor gene, p53, which is mutated in nearly half of cancers.

<span class="mw-page-title-main">LI-RADS</span> LI Rads for the Classification of HCC

The Liver Imaging Reporting and Data System is a quality assurance tool created and trademarked by the American College of Radiology in 2011 to standardize the reporting and data collection of CT and MR imaging patients at risk for hepatocellular carcinoma (HCC), or primary cancer of the liver cells. It provides a standardized framework for classification of liver lesions by a radiologist, and only applies in patients with chronic liver disease, the main risk factor for liver cancer. The hierarchical classification, from LR1 to LR5, is based on specific imaging features of the lesion in question, and corresponds to the degree of suspicion for malignancy. For example, a lesion with features corresponding to the highest category, LR5, is "definitely" HCC. Importantly, the increasing acceptance of the LI-RADS system of reporting by referring clinicians has reduced the need for tissue biopsy confirmation of cancer in patients with chronic liver disease.

Transarterial bland embolization is a catheter-based tumor treatment of the liver. In this procedure, a variety of embolizing agents can be delivered through the tumor’s feeding artery in order to completely occlude the tumor’s blood supply. The anti-tumor effects are solely based on tumor ischemia and infarction of tumor tissue, as no chemotherapeutic agents are administered. The rationale for the use of bland embolization for hepatocellular carcinoma(HCC) and/or other hyper-vascular tumors is based on the fact that normal liver receives a dual blood supply from the hepatic artery (25%) and the portal vein (75%). As the tumor grows, it becomes increasingly dependent on the hepatic artery for blood supply. Once a tumor nodule reaches a diameter of 2 cm or more, most of the blood supply is derived from the hepatic artery. Therefore, bland embolization and transarterial chemoembolization (TACE) consist of the selective angiographic occlusion of the tumor arterial blood supply with a variety of embolizing agents, with or without the precedence of local chemotherapy infusion. The occlusion by embolic particles results in tumor hypoxia and necrosis, without affecting the normal hepatic parenchyma.

References

  1. 1 2 3 Torbenson, Michael (2012). "Fibrolamellar Carcinoma: 2012 Update". Scientifica. 2012: 743790. doi: 10.6064/2012/743790 . PMC   3820672 . PMID   24278737.
  2. 1 2 3 O'Neill, Allison F.; Church, Alanna J.; Perez-Atayde, Antonio R.; Shaikh, Raja; Marcus, Karen J.; Vakili, Khashayar (August 2021). "Fibrolamellar carcinoma: An entity all its own". Current Problems in Cancer. 45 (4): 100770. doi:10.1016/j.currproblcancer.2021.100770. PMID   34272087. S2CID   236001418.
  3. ↑ Zack, Travis; Losert, Kurt P.; Maisel, Samantha M.; Wild, Jennifer; Yaqubie, Amin; Herman, Michael; Knox, Jennifer J.; Mayer, Robert J.; Venook, Alan P.; Butte, Atul; O'Neill, Allison F.; Abou-Alfa, Ghassan K.; Gordan, John D. (23 March 2023). "Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data". npj Precision Oncology. 7 (1): 29. doi: 10.1038/s41698-023-00371-2 . PMC   10034241 . PMID   36959495.
  4. ↑ Lalazar, Gadi; Simon, Sanford (February 2018). "Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms". Seminars in Liver Disease. 38 (1): 051–059. doi:10.1055/s-0037-1621710. PMC   6020845 . PMID   29471565.
  5. 1 2 "What is Fibrolamellar Carcinoma?". Fibrolamellar Cancer Foundation. 20 February 2021. Retrieved 2023-01-10.
  6. ↑ "Teen Makes Genetic Discovery of Her Own Rare Cancer". NBC News . 16 April 2014.
  7. 1 2 Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim II, Gleason CE, Murphy JM, Rosenberg BR, Teegan L, Takacs CN, Botero S, Belote R, Germer S, Emde AK, Vacic V, Bhanot U, LaQuaglia MP, Simon SM (28 February 2014). "Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma". Science. 343 (6174): 1010–4. Bibcode:2014Sci...343.1010H. doi:10.1126/science.1249484. PMC   4286414 . PMID   24578576.
  8. 1 2 Graham, Rondell P; Jin, Long; Knutson, Darlene L; Kloft-Nelson, Sara M; Greipp, Patricia T; Waldburger, Nina; Roessler, Stephanie; Longerich, Thomas; Roberts, Lewis R; Oliveira, Andre M; Halling, Kevin C; Schirmacher, Peter; Torbenson, Michael S (June 2015). "DNAJB1-PRKACA is specific for fibrolamellar carcinoma". Modern Pathology. 28 (6): 822–829. doi: 10.1038/modpathol.2015.4 . PMID   25698061.
  9. ↑ Xu, Lei; Hazard, Florette K.; Zmoos, Anne-Flore; Jahchan, Nadine; Chaib, Hassan; Garfin, Phillip M.; Rangaswami, Arun; Snyder, Michael P.; Sage, Julien (1 January 2015). "Genomic analysis of fibrolamellar hepatocellular carcinoma". Human Molecular Genetics. 24 (1): 50–63. doi:10.1093/hmg/ddu418. PMC   4262492 . PMID   25122662.
  10. ↑ Dinh TA, Vitucci EC, Wauthier E, Graham RP, Pitman WA, Oikawa T, Chen M, Silva G, Greene KG, Torbenson MS, Reid LM, Sethupathy P (2017) Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. Sci Rep 7:44653. doi: 10.1038/srep44653
  11. 1 2 Kastenhuber, Edward R.; Lalazar, Gadi; Houlihan, Shauna L.; Tschaharganeh, Darjus F.; Baslan, Timour; Chen, Chi-Chao; Requena, David; Tian, Sha; Bosbach, Benedikt; Wilkinson, John E.; Simon, Sanford M.; Lowe, Scott W. (12 December 2017). "DNAJB1–PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma". Proceedings of the National Academy of Sciences. 114 (50): 13076–13084. Bibcode:2017PNAS..11413076K. doi: 10.1073/pnas.1716483114 . PMC   5740683 . PMID   29162699.
  12. ↑ Engelholm, Lars H.; Riaz, Anjum; Serra, Denise; Dagnæs-Hansen, Frederik; Johansen, Jens V.; Santoni-Rugiu, Eric; Hansen, Steen H.; Niola, Francesco; Frödin, Morten (December 2017). "CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1–Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma". Gastroenterology. 153 (6): 1662–1673.e10. doi: 10.1053/j.gastro.2017.09.008 . PMC   5801691 . PMID   28923495.
  13. ↑ Neumayer, Christoph; Ng, Denise; Jiang, Caroline S.; Qureshi, Adam; Lalazar, Gadi; Vaughan, Roger; Simon, Sanford M. (4 January 2023). "Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA". Clinical Cancer Research. 29 (1): 271–278. doi:10.1158/1078-0432.CCR-22-1851. PMC   9811160 . PMID   36302174.
  14. ↑ Yen, JB.; Chang, KW. (2009). "Fibrolamellar hepatocellular carcinoma- report of a case". Chang Gung Med J. 32 (3): 336–9. PMID   19527614.
  15. ↑ Collier, N.A.; Bloom, S.R.; Hodgson, H.J.F.; Weinbren, K.; Lee, Y.C.; Blumgart, L.H. (March 1984). "Neurotensin Secretion by Fibrolamellar Carcinoma of the Liver". The Lancet. 323 (8376): 538–540. doi:10.1016/s0140-6736(84)90934-6. PMID   6199633. S2CID   28566123.
  16. ↑ Paradinas, F J; Melia, W M; Wilkinson, M L; Portmann, B; Johnson, P J; Murray-Lyon, I M; Williams, R (25 September 1982). "High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma". BMJ. 285 (6345): 840–842. doi:10.1136/bmj.285.6345.840. PMC   1499744 . PMID   6288165.
  17. 1 2 Malouf, G; Falissard, B; Azoulay, D; Callea, F; Ferrell, L D; Goodman, Z D; Hayashi, Y; Hsu, H-C; Hubscher, S G; Kojiro, M; Ng, I O; Paterson, A C; Reynes, M; Zafrani, E-S; Emile, J-F (1 June 2009). "Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts?". Journal of Clinical Pathology. 62 (6): 519–524. doi:10.1136/jcp.2008.062620. PMID   19155239. S2CID   206987786.
  18. 1 2 Levin, Solomon N.; Tomasini, Michael D.; Knox, James; Shirani, Mahsa; Shebl, Bassem; Requena, David; Clark, Jackson; Heissel, Søren; Alwaseem, Hanan; Surjan, Rodrigo; Lahasky, Ron; Molina, Henrik; Torbenson, Michael S.; Lyons, Barbara; Migler, Rachael D.; Coffino, Philip; Simon, Sanford M. (23 June 2023). "Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma". Science Advances. 9 (25): eadg7038. Bibcode:2023SciA....9G7038L. doi:10.1126/sciadv.adg7038. PMC   10284549 . PMID   37343102.
  19. 1 2 3 4 5 6 Berkovitz, Amichai; Migler, Rachael D.; Qureshi, Adam; Rosemore, Carly; Torbenson, Michael S.; Vaughan, Roger; Marcotte, Erin; Simon, Sanford M. (December 2022). "Clinical and demographic predictors of survival for fibrolamellar carcinoma patients—A patient community, registry‐based study". Hepatology Communications. 6 (12): 3539–3549. doi:10.1002/hep4.2105. PMC   9701473 . PMID   36245434.
  20. 1 2 Simon, Sanford M. (May 2023). "Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma". Nature Reviews Cancer. 23 (5): 335–346. doi:10.1038/s41568-023-00554-w. PMC   10022574 . PMID   36932129.
  21. 1 2 3 "Home". The Fibrolamellar Registry.
  22. ↑ Chen, Krista Y.; Popovic, Aleksandra; Hsiehchen, David; Baretti, Marina; Griffith, Paige; Bista, Ranjan; Baghdadi, Azarakhsh; Kamel, Ihab R.; Simon, Sanford M.; Migler, Rachael D.; Yarchoan, Mark (30 October 2022). "Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors". Cancers. 14 (21): 5347. doi: 10.3390/cancers14215347 . PMC   9655068 . PMID   36358766.
  23. ↑ Shebl, Bassem; Ng, Denise; Lalazar, Gadi; Rosemore, Carly; Finkelstein, Tova M.; Migler, Rachael D.; Zheng, Guangrong; Zhang, Peiyi; Jiang, Caroline S.; Qureshi, Adam; Vaughan, Roger; Yarchoan, Mark; de Jong, Ype P.; Rice, Charles M.; Coffino, Philip; Ortiz, Michael V.; Zhou, Daohong; Simon, Sanford M. (8 September 2022). "Targeting BCL-XL in fibrolamellar hepatocellular carcinoma". JCI Insight. 7 (17): e161820. doi:10.1172/jci.insight.161820. PMC   9536265 . PMID   36073545.
  24. ↑ "Fibrolamellar treatment options". Fibrolamellar Cancer Foundation. 27 January 2021. Retrieved 2023-01-10.
  25. ↑ Lafaro KJ, Pawlik TM (2015) Fibrolamellar hepatocellular carcinoma: current clinical perspectives. J Hepatocell Carcinoma 2:151–157 doi: 10.2147/JHC.S75153
  26. ↑ Stipa F, Yoon SS, Liau KH, et al. (March 2006). "Outcome of patients with fibrolamellar hepatocellular carcinoma". Cancer. 106 (6): 1331–8. doi: 10.1002/cncr.21703 . PMID   16475212.
  27. ↑ Edmondson HA (1956) Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child 91(2):168–186
  28. ↑ Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 46(2):372–379
  29. ↑ Bosman FT (2010) World Health Organization. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: International Agency for Research on Cancer
  30. ↑ "Teen Makes Genetic Discovery of Her Own Rare Cancer". NBC News. 16 April 2014.
  31. ↑ "Fibrolamellar Liver Cancer Research". YouTube .
  32. ↑ "Senate Appropriation Hearings on the NIH: Francis Collins". YouTube .
  33. ↑ "Launching of the Precision Medicine Initiative Jan 30, 2015". YouTube .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.